In the current study, we developed a vaccine composed of the sequence of amino acids 150–156 of CTGF (common to both human and mouse) to attenuate the development of renal fibrosis, and then verified the efficacy of this vaccine in two renal fibrosis mouse models: adenine-induced CKD and unilateral ureteral obstruction (UUO) models. Here, CCN2 is linked to chronic kidney disease.